Don't say PCOS anymore, say PCOM. Since Tuesday, May 12, 2026, polycystic ovary syndrome has officially been given a new name: Polycystic Ovarian Metabolic Syndrome. Announced at the European Congress of Endocrinology in Prague and published simultaneously in the prestigious journal The Lancet, this change is the result of fourteen years of international consensus bringing together more than fifty learned societies and patient groups from around the world. A shift that might seem purely semantic, but which in fact corrects a persistent misnomer that has long been responsible for diagnostic odysseys and inappropriate management. What does this new acronym mean, why is this change happening now, and what does it actually mean for the 170 million women affected worldwide? An in-depth look.
PCOS becomes PCOM: what does the official announcement of May 12, 2026, say?
A historic announcement at the European Congress of Endocrinology in Prague
It was during the European Congress of Endocrinology currently being held in Prague that the international medical community officially announced, on Tuesday, May 12, 2026, the abandonment of the term "polycystic ovary syndrome". The announcement was immediately followed by publication in The Lancet, one of the most influential scientific journals in the world. At the heart of the process: Professor Helena Teede, director of the Monash Centre for Health Research and Implementation in Melbourne, who has spent decades studying this condition and documenting the practical consequences of its historical name on patient management.
14 years of international consensus: 50 learned societies mobilized
This change is no media stunt. It is based on fourteen years of collaborative work involving more than fifty international learned societies, clinicians, researchers, and especially patient groups from around the world. A consultation conducted between 2015 and 2023 involving more than 7,700 participants across six continents confirmed the scale of the problem: 85.6% of patients surveyed and 76.1% of healthcare professionals were in favor of a name change. The terms "endocrine" and "metabolic" received the strongest support for inclusion in the new name.
A 3-year transition period until the 2028 guidelines
Although the new name is effective immediately, a three-year transition period is planned to give healthcare professionals, governments, and researchers time to adopt it. A global awareness campaign will accompany this change, before the PCOM acronym is fully integrated into the update of international recommendations planned for 2028.
PCOM: what does this new acronym mean?
Polycystic Ovarian Metabolic Syndrome: decoding it letter by letter
Each word in the new acronym has been carefully considered. Syndrome reminds us that it is a coherent set of clinical manifestations, not a single disease. Metabolic, placed first, signals a major repositioning: the condition is no longer defined primarily by the ovaries, but by its effects on the entire metabolism. Ovarian preserves the reproductive dimension, which remains central to its clinical presentation. Polycystic finally recognizes that several hormonal axes are simultaneously disrupted, from the hypothalamic-pituitary axis to the adrenals and the pancreas.
Why "metabolic" takes first place
This lexical choice is not arbitrary. Women with the condition frequently present insulin resistance, an increased risk of type 2 diabetes, lipid abnormalities, and a significant cardiovascular risk. Anti-müllerian hormone levels have emerged as a key biomarker, and the metabolic dimension is now considered a central determinant of long-term prognosis. By placing "metabolic" first, the new nomenclature imposes a multidisciplinary view of the condition, far beyond the gynecological lens alone.
Why "polycystic" is disappearing: the historical error corrected
Established in 1935 by gynecologists Stein and Leventhal, the term "polycystic ovaries" is based on a misinterpreted ultrasound observation. What the early clinicians took for cysts are not cysts. They are actually a multitude of antral follicles whose development is incomplete: immature oocytes stalled in their maturation, not pathological cystic cavities. The historical name thus perpetuated for nearly a century the idea of a localized ovarian disease, obscuring its metabolic, endocrine, and systemic dimensions.
A condition affecting 1 in 8 women worldwide
170 million women affected
PCOM affects one in eight women worldwide, or approximately 170 million women. According to Inserm, it affects 10 to 13% of women of childbearing age in France and is the leading female endocrine disorder. Yet, up to 70% of cases remain undiagnosed to date. This massive underreporting is one of the major arguments in favor of the name change: a syndrome perceived as "gynecological" is less systematically investigated by general practitioners or endocrinologists, even though its consequences extend far beyond the reproductive sphere.
Leading cause of female infertility
PCOM is now recognized as the leading cause of female infertility worldwide. Oligo-anovulation (infrequent or absent cycles) limits the regular release of mature oocytes, complicating spontaneous conception. However, and this is an essential message to remember: the vast majority of women with the condition will be able to conceive, sometimes spontaneously, sometimes with appropriate medical support.
A diagnostic odyssey linked to the old name
Many women describe a diagnostic journey spanning several years, sometimes more than a decade. Downplayed symptoms, examinations focused solely on the ovarian aspect, metabolic manifestations (abdominal weight gain, fatigue, cravings) not linked to the syndrome: all these signals slipped through the cracks because of an overly restrictive name. This is precisely the odyssey the new nomenclature aims to reduce.
Be Healthy advice
If you were diagnosed with PCOS before May 12, 2026, your medical record remains fully valid. PCOM refers to exactly the same condition. There is no need to see a doctor again to "re-request" a diagnosis or to question your current management. The only change to anticipate: your health record, medical reports, and future prescriptions will gradually mention the new term. It is a simple vocabulary update—not a new diagnosis.
What PCOM actually changes for affected women
A diagnosis less focused on the ovaries
With the new name, ovarian imaging (pelvic ultrasound) remains a useful examination, but it is no longer the central element of the diagnosis. Diagnostic criteria based on cycle irregularity and clinical or biological hyperandrogenism are gaining importance. A woman with irregular cycles, persistent acne, and a suggestive hormonal profile can be diagnosed with PCOM even without characteristic ovarian morphology on ultrasound.
Strengthened multidisciplinary management
The new name calls for more systematic coordination between the gynecologist, endocrinologist, nutritionist, and general practitioner. The 2023 international recommendations, already published by Professor Teede's team, emphasize the need for rigorous monitoring of body mass index, blood pressure, and metabolic parameters (blood sugar, lipid profile), as well as periodic screening for depression, anxiety, and obstructive sleep apnea.
Greater recognition of metabolic symptoms
Insulin resistance, abdominal weight gain, and glucose metabolism disorders are no longer considered peripheral "comorbidities," but central manifestations of the condition. This changes how doctors explore symptoms and guide patients toward appropriate nutritional and lifestyle interventions from the very first consultations.
PCOM symptoms (formerly PCOS) to know
Ovulation disorders and irregular cycles
Long cycles (beyond 35 days), widely spaced (oligomenorrhea), or absent (amenorrhea) remain the most common signs. These irregularities reflect rare or absent ovulation and alone explain the majority of infertility cases associated with PCOM.
Hyperandrogenism: acne, hirsutism, hair loss
Excess androgens ("male" hormones such as testosterone) cause several characteristic skin manifestations: persistent acne, especially in adulthood; excess body hair (hirsutism) on the face, chest, or abdomen, affecting up to 70% of affected women; and androgenetic hair loss.
Metabolic manifestations: insulin resistance, abdominal overweight
Approximately 70% of affected women have insulin resistance. In practical terms, the body produces more insulin to maintain normal blood sugar, which promotes fat storage, particularly in the abdominal area, and gradually establishes a metabolic cycle that is difficult to reverse. Post-meal fatigue, sugar cravings, and difficulty losing weight despite efforts are common signs.
Mental health consequences
PCOM is frequently accompanied by anxiety, depressive symptoms, and impaired self-esteem, partly linked to visible manifestations (acne, body hair, weight) and the often distressing journey leading to diagnosis. This dimension is now integrated into follow-up recommendations.
The key role of metabolism in PCOM: a closer look at insulin resistance
Why 70% of affected women have insulin resistance
Insulin resistance refers to the reduced sensitivity of cells to insulin, the hormone that regulates blood sugar. To compensate, the pancreas produces more. This phenomenon, common in PCOM, is now considered a central mechanism—which fully justifies highlighting the term "metabolic" in the new name.
The vicious cycle: insulin → androgens → disrupted ovulation
Hyperinsulinemia stimulates androgen production by the ovaries and reduces hepatic production of SHBG (the protein that "captures" circulating testosterone). The result: more free testosterone, which worsens clinical hyperandrogenism and disrupts the maturation of ovarian follicles. Breaking this cycle requires simultaneously addressing insulin sensitivity, diet, and overall hormonal balance.
Nutritional solutions validated by the 2023 guidelines
The 2023 international recommendations place a low glycemic index diet, regular physical activity, and weight management at the forefront of management. Depending on individual profiles, moderate weight loss (5 to 10% of initial weight) may be enough to restore regular ovulation in overweight women.
Medical advice required
A diagnosis of PCOM can only be made by a healthcare professional (general practitioner, gynecologist, endocrinologist) based on a blood hormonal profile, a clinical assessment of symptoms, and, if necessary, a pelvic ultrasound. Any suggestive symptom (irregular cycles, persistent acne after age 25, excess body hair, unexplained weight gain) should be the subject of a medical consultation. The general practitioner is the first point of contact and will refer the patient to a gynecologist or endocrinologist as needed. The earlier the diagnosis, the more effective the long-term support.
Dietary supplements never replace medical follow-up or prescribed treatment. They are part of a comprehensive support approach, complementing lifestyle and dietary measures and medical management.
Supporting hormonal and metabolic balance: the natural approach
Myo-inositol and D-chiro-inositol: 2 allies for ovarian balance
Inositols are a family of glucose-related molecules naturally present in the body and involved in insulin cell signaling. Myo-inositol and D-chiro-inositol are the two most studied forms in the context of PCOM. Numerous studies published on PubMed have explored their ability to support insulin sensitivity and contribute to female hormonal balance. This is precisely why OVA Support combines them in its formula.
The 40:1 ratio: why it makes the difference
In the human body, there is naturally a physiological ratio of 40:1 between myo-inositol and D-chiro-inositol. Replicating this ratio in supplementation has been the subject of extensive scientific literature. OVA Support contains 4,000 mg of myo-inositol and 100 mg of D-chiro-inositol per daily dose, precisely respecting this ratio. This formulation precision is rare on the dietary supplement market.
A low glycemic index diet
Adopting a low glycemic index diet forms the foundation of nutritional support. In practical terms: favor whole grains, legumes, vegetables, fresh fruit, and quality proteins; limit refined sugars, sugary drinks, and ultra-processed products. This approach supports insulin sensitivity and helps stabilize weight.
The role of omega-3s in chronic inflammation
PCOM is frequently accompanied by low-grade chronic inflammation that worsens insulin resistance. Omega-3 fatty acids (EPA and DHA) help maintain the body's inflammatory balance. Supplementation can effectively complement a diet already rich in fatty fish, flaxseeds, or rapeseed oil.
PCOM FAQ
Are PCOS and PCOM exactly the same thing?
Yes. PCOM refers to exactly the same condition as PCOS. Only the name changes, not the condition itself, its diagnostic criteria, or its management principles. The change aims to better reflect the multisystem nature of the condition and correct the biases perpetuated by the old name.
Do I need to be re-diagnosed if I have already been diagnosed with PCOS?
No. Your diagnosis remains valid. Your medical reports mentioning "PCOS" retain their full validity. During your next consultations, the term will gradually change to "PCOM" in your file, following the three-year transition period planned until the new 2028 recommendations.
Can PCOM be cured?
PCOM is a chronic condition for which there is currently no curative treatment. However, comprehensive and personalized management—combining medical follow-up, dietary adjustments, physical activity, stress management, and occasional support from certain micronutrients—allows many women to significantly reduce symptoms and permanently improve their quality of life.
Can you get pregnant with PCOM?
Yes, in the vast majority of cases. Although PCOM is the leading cause of female infertility, it is not synonymous with sterility. Many women conceive spontaneously; others benefit from medical support (ovulation stimulation, metabolic adjustments) that restores satisfactory fertility. Medical assisted reproduction may be offered in certain situations.
When to see a doctor if you suspect PCOM?
Any persistent combination of irregular cycles, adult acne, excess body hair, hair loss, or unexplained weight gain warrants a consultation. The general practitioner is the first point of contact and will refer the patient to a gynecologist or endocrinologist as needed. The earlier the diagnosis, the more effective the long-term support.
Conclusion: a name change that opens a new era
The shift from PCOS to PCOM is not a semantic detail. It is the official recognition that this syndrome, which affects one in eight women worldwide, is first and foremost a complex metabolic and endocrine condition, with manifestations that vary depending on individual profiles. A change in perspective that should, in time, shorten diagnostic delays, improve care coordination, and promote more comprehensive approaches. At Be Healthy, this evolution aligns with a long-held conviction: supporting women's health requires a multidimensional view that integrates hormonal balance, metabolism, diet, and quality of life. Our OVA Support formula, combining myo-inositol and D-chiro-inositol at the physiological 40:1 ratio, is fully aligned with this approach. For women seeking even more comprehensive gynecological support, the Gyneco Prevention Protocol combines targeted probiotics and hormonal support.
Warning. This article is published for informational purposes and does not constitute medical advice or a substitute for a consultation with a healthcare professional. Dietary supplements should be used as part of a varied and balanced diet and a healthy lifestyle. They are not a substitute for prescribed medical treatment. Anyone presenting symptoms suggestive of PCOS (formerly PCOS) should consult their doctor to establish a diagnosis and receive appropriate care. In case of pregnancy, breastfeeding, or ongoing treatment, ask your doctor or pharmacist for advice before taking any supplements.
Sources (5 references)
- Teede H.J. et al., The Lancet, publication of May 12, 2026, on the official renaming of PCOS to PCOS — read the publication
- Inserm, reference guide on polycystic ovary syndrome — read the guide
- Teede H.J. et al., Recommendations from the 2023 international evidence-based guidelines for the assessment and management of polycystic ovary syndrome, J Clin Endocrinol Metab. 2023;108:2447-2469
- Monash Centre for Health Research and Implementation, Monash University, Australia — learn more
- PubMed database, clinical studies on myo-inositol and D-chiro-inositol in PCOS/PCOS